secwatch.observer — SEC 8-K summary
======================================

Issuer:     Lexeo Therapeutics, Inc. (LXEO)
CIK:        0001907108
Form:       8-K
Filed at:   2024-12-19T23:59:59+00:00
Accession:  0000950170-24-138224
Event type: leadership
Sentiment:  neutral
Materiality: 0.60
Item codes: 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Lexeo Therapeutics appoints Dr. Kyle Rasbach as CFO effective Dec 18, 2024
--------------------------------------------------------------------------

- Dr. Kyle Rasbach appointed CFO; CEO R. Nolan Townsend steps down as principal financial officer.
- Initial base salary $480,000, discretionary bonus target 40%; receives 40,875 RSUs and options for 245,250 shares.
- Rasbach previously CFO at Zentalis, portfolio manager at Eventide, and analyst at T. Rowe Price and Cowen.
- Severance includes 12 months salary, COBRA, and potential equity acceleration; if over $120M financing, unvested equity may continue vesting 24 months.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1907108/000095017024138224/0000950170-24-138224-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1907108/000095017024138224/lxeo-20241218.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-138224

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer